Biotechnology Valuation & Investing : Biotech Valuation & Investing, Paperbac...

by Dimitrios Iliopoulos

$80 · Offered by eBay

Biotechnology Valuation & Investing : Biotech Valuation & Investing, Paperback by Iliopoulos, Dimitrios; Hsu, Jason, ISBN 1539874389, ISBN-13 9781539874386, Like New Used, Free shipping in the US Janet Yellen, the Fed Chair, recently said that the valuations of small-cap biotechnology companies are substantially stretched. Biotechnology is a relatively new science and during the last few years there is an increasing number of new biotech start-up companies and also M&A activity between biotech start-ups and large biotechnology and pharmaceutical companies. Few years ago, we observed one of the largest acquisitions in the biotech sector, by having Amgen buying Onyx Pharmaceuticals for more than $9 billion dollars. More recently, Moderna Therapeutics, a biotech company developing mRNA therapeutics, broke the record of VC funding, raising $450 million dollars in a single round of funding, without having a product in the market. All these recent events raise an important question: what are the valuation financial models used in the biotechnology industry? How could we value a company having negative cash flows for several years, without any product in the market? How do we value a company developing a CRISPR therapeutics currently in the preclinical level? Is there any difference on valuating a phase II drug against arthritis vs a phase II anti-cancer drug? This book is aiming to answer these essential questions by describing the key aspects of the drug discovery process, includi

• Publisher: CreateSpace
• Year: 2016
• Binding: Paperback
• ISBN: 9781539874386
• Condition: Fine

Found via Rare Books Intel, a search across rare-book dealers, auction houses and marketplaces worldwide.